CTOs on the Move

AllerVie

www.allervie.com

 
AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 12 states in 76 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.allervie.com
  • 4975 Preston Park Boulevard Suite 800
    Plano, TX USA 75093
  • Phone: 256.539.6536

Executives

Name Title Contact Details
Weily Soong
 Chief Research Innovation Officer Profile

Similar Companies

Eastern Maine Healthcare Systems

Eastern Maine Healthcare Systems (EMHS) is committed to delivering quality and cost-effective patient care despite the difficult healthcare environment that's challenging the nation and the residents of Maine.

SW Carson Consulting Inc

SW Carson Consulting Inc is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Srt Group

HealthWorks

HealthWorks is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Symbiomix Therapeutics

Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.